Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Earnings announcement soon...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by PoorOpinionon Feb 27, 2017 10:06pm
153 Views
Post# 25902801

RE:RE:RE:RE:RE:Earnings announcement soon...

RE:RE:RE:RE:RE:Earnings announcement soon...I just noticed in the new presentation that they dropped the page entitled "Early performance indicators" which had been in the two previous presentations and was showing sales of Yosprala. My guess is you pull it out if the numbers arent so hot, you leave it in and update it if things are on track. Over-exuberance may well be off the table.

snootchybootchy wrote: I watched the webcast of the presentation Aralez presented at the RBC Markets Global Healthcare Conference.  Mr. Adams mentioned (a few times) that the year-end conference call will be scheduled for early March.

Not sure if it was my imagination but he seemed to be playing down any potential over-exuberance regarding the uptake of Yosprala.  He mentioned several times that they're still in the early days of the launch and they are continuing to educate the medical community on the benefits of Yosprala and securing greater access coverage for the drug.  On the other hand, I thought he seemed very optimistic about the prospects for Zontivity.  Will be interested in hearing any guidance for 2017.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities